Sr. No.	Received from	Pending at the end of last month	Received	Resolved*	Total Pending #	Pending complaints >3months	Average Resolution time^ (in days)
1	Directly from Investors	0	0	0	0	0	0
2	SEBI (SCORES)	0	0	0	0	0	0
3	Other Sources (if any)	0	0	0	0	0	0
	Grand Total	0	0	0	0	0	0

Sr. No.	Month	Carried forward from previous month	Received	Resolved*	Pending#
1	Jun, 2026	0	0	0	0
2	Jul, 2026	0	0	0	0
3	Aug, 2026	0	0	0	0
	Grand Total	0	0	0	0

Sr. No.	Fin. Year	Received	Resolved*
1	2022-23	1	1
2	2023-24	0	0
3	2024-25	0	0
4	2025-26	1	1
	Grand Total	2	2

Sun Pharma Group Stocks

1 Yr CAGR 6.14%

3 Yr CAGR 12.98%

Total Companies 3

List of Sun Pharma Stocks as on 02-Nov-2026

Filter

	Company Name	DeciZen	CMP	Price Change	Market Cap (Cr)	52 Week High	52 Week Low	ROE	P/E Ratio	P / BV	EV/ EBITDA
1	Sun Pharma. Inds.	4 Q V+ PT	1,778	0.87%	4,26,662 Large Cap	2,048 31 Jul, 26	1,584 29 Jan, 26	14.80	38.91	4.78	20.11	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Zenotech Labs.	4 Q V+ PT	38.51	1.48%	235 Small Cap	54.14 31 Oct, 25	33.55 30 Mar, 26	-0.92	-	2.55	40.04	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	Sun Pharma Adv. Res	4 Q V+ PT	177	-3.47%	5,741 Small Cap	289 08 Jul, 26	108 23 Mar, 26	279.64	3.62	4.36	3.83	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History

Top Business Houses

Tata

26 Companies

Market Cap: ₹ 25,76,034 Cr.

1 Yr CAGR -6.84%

3 Yr CAGR 2.07%

Mukesh Ambani

8 Companies

Market Cap: ₹ 17,27,645 Cr.

1 Yr CAGR -23.08%

3 Yr CAGR -5.44%

Adani

7 Companies

Market Cap: ₹ 15,96,901 Cr.

1 Yr CAGR 15.40%

3 Yr CAGR 11.47%

Bharti

3 Companies

Market Cap: ₹ 14,11,114 Cr.

1 Yr CAGR -6.84%

3 Yr CAGR 28.00%

Bajaj

12 Companies

Market Cap: ₹ 13,44,185 Cr.

1 Yr CAGR -12.30%

3 Yr CAGR 14.21%

HDFC

4 Companies

Market Cap: ₹ 13,22,410 Cr.

1 Yr CAGR -14.22%

3 Yr CAGR 2.35%

ICICI

4 Companies

Market Cap: ₹ 12,73,032 Cr.

1 Yr CAGR -5.82%

3 Yr CAGR 4.93%

PSU - SBI

4 Companies

Market Cap: ₹ 11,98,558 Cr.

1 Yr CAGR -17.55%

3 Yr CAGR 3.14%

News about Sun Pharma Stocks in India

Oct, 2026

Sun Pharma. Inds. - Quaterly Results

The sales surged to Rs. 61419.20 millions, up 35.04% for the September 2026 quarter as against Rs. 45481.10 millions during the corresponding quarter previous year.Profit after tax for the quarter ended September 2026 reported a huge growth of 54.42% to Rs. 8712.90 millions from Rs. 5642.20 millions.Operating Profit saw a handsome growth to 17957.40 millions from 12563.80 millions in the quarter ended September 2026.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202609	202509	% Var	202609	202509	% Var	202603	202503	% Var
Sales	61419.20	45481.10	35.04	118830.50	101429.90	17.16	207546.40	229774.00	-9.67
Other Income	810.10	727.90	11.29	2211.80	1765.00	25.31	4193.30	3791.40	10.60
PBIDT	17957.40	12563.80	42.93	39001.20	32696.20	19.28	66000.20	72168.40	-8.55
Interest	2769.60	2483.30	11.53	5554.40	4867.50	14.11	9478.40	9538.90	-0.63
PBDT	15187.80	10080.50	50.67	33131.50	24952.30	32.78	51058.40	62629.50	-18.48
Depreciation	3157.90	3363.00	-6.10	6237.10	6472.20	-3.63	13117.20	12867.40	1.94
PBT	12029.90	6717.50	79.08	26894.40	18480.10	45.53	37941.20	49762.10	-23.75
TAX	3317.00	1075.30	208.47	7030.10	5387.30	30.49	11707.00	7481.30	56.48
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PAT	8712.90	5642.20	54.42	19864.30	13092.80	51.72	26234.20	42280.80	-37.95
Equity	2399.30	2399.30	0.00	2399.30	2399.30	0.00	2399.30	2399.30	0.00
PBIDTM(%)	29.24	27.62	5.84	32.82	32.24	1.82	31.80	31.41	1.25

Oct, 2026

Sun Pharma’s consolidated net profit falls 36% in Q2

The total consolidated income of the company has increased by 11.83% at Rs 16,716.03 crore for Q2FY27

Oct, 2026

Sun Pharma shines on getting USFDA’s nod for supplemental biologics license application for ‘ILUMYA’

The approval is supported by Phase 3 INSPIRE-1 and INSPIRE-2 clinical studies

Oct, 2026

Sun Pharma gets USFDA’s nod for supplemental biologics license application for ‘ILUMYA’

The approval is supported by Phase 3 INSPIRE-1 and INSPIRE-2 clinical studies

Oct, 2026

Zenotech Labs. - Quaterly Results

The sales slipped to Rs. 71.48 millions, down -36.38% for the September 2026 quarter as against Rs. 112.36 millions during the year-ago period.The Net Loss for the quarter ended September 2026 is Rs. -25.72 millions as compared to Net Loss of Rs. -8.37 millions of corresponding quarter ended September 2025Operating profit Margin for the quarter ended September 2026 slipped to -16.05% as compared to 29.90% of corresponding quarter ended September 2025

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202609	202509	% Var	202609	202509	% Var	202603	202503	% Var
Sales	71.48	112.36	-36.38	177.60	208.79	-14.94	436.14	430.47	1.32
Other Income	4.24	7.00	-39.43	8.60	12.88	-33.23	23.09	15.49	49.06
PBIDT	-16.05	29.90	-153.68	-3.03	60.40	-105.02	114.98	157.29	-26.90
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PBDT	-16.05	30.40	-152.80	-3.03	60.90	-104.98	113.03	176.52	-35.97
Depreciation	18.15	17.82	1.85	37.17	35.56	4.53	71.13	69.60	2.20
PBT	-34.20	12.58	-371.86	-40.20	25.34	-258.64	41.90	106.92	-60.81
TAX	-8.48	20.95	-140.48	-9.93	23.82	-141.69	52.61	50.79	3.58
Deferred Tax	-8.48	42.22	-120.09	-9.93	42.87	-123.16	47.72	25.86	84.53
PAT	-25.72	-8.37	207.29	-30.27	1.52	-2091.45	-10.71	56.13	-119.08
Equity	610.31	610.31	0.00	610.31	610.31	0.00	610.31	610.31	0.00
PBIDTM(%)	-22.45	26.61	-184.38	-1.71	28.93	-105.90	26.36	36.54	-27.85

Oct, 2026

Sun Pharmaceutical Industries informs about allotment of NCDs

Further to earlier communication dated 12 October 2026, Sun Pharmaceutical Industries has informed that the Company has today, i.e., 26 October 2026, completed the allotment, on a private placement basis, of rated, listed, unsecured, redeemable, non-convertible debentures (NCDs) having an aggregate face value of INR 7,816 crore, comprising: 1. Series A NCDs having an aggregate face value of INR 2,003 crore; and 2. Series B NCDs having an aggregate face value of INR 5,813 crore. The base issue size of INR 7,000 crore was fully subscribed and, based on the bids received and accepted, the Company exercised the greenshoe option to the extent of ?816 crore, out of the greenshoe option of up to INR 3,000 crore. The details required under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as Annexure A.

The above information is a part of company’s filings submitted to BSE.

Track Now:

5 Star Companies Large Cap Companies Mid Cap Companies Small Cap Companies Nifty Microcap Companies Top IT Companies Tax saver funds Analyze your Equity Funds Nifty Index Funds

You have 2 views remaining as a Guest User. Login | Register Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Current Complaints

*Inclusive of complaints of previous months resolved in the current month. #Inclusive of complaints pending as on the last day of the month.

*Inclusive of complaints of previous months resolved in the current month. #Inclusive of complaints pending as on the last day of the year.

Sun Pharma Group Stocks

Top Business Houses

Tata

Mukesh Ambani

Adani

Bharti

Bajaj

HDFC

ICICI

PSU - SBI

News about Sun Pharma Stocks in India

Sun Pharma. Inds. - Quaterly Results

Sun Pharma’s consolidated net profit falls 36% in Q2

Sun Pharma shines on getting USFDA’s nod for supplemental biologics license application for ‘ILUMYA’

Sun Pharma gets USFDA’s nod for supplemental biologics license application for ‘ILUMYA’

Zenotech Labs. - Quaterly Results

Sun Pharmaceutical Industries informs about allotment of NCDs

Track Now:

Trending Blogs